Pular para o conteúdo
Merck
Todas as fotos(2)

Documentos Principais

A9732

Sigma-Aldrich

Anti-ATP13A2 (C-terminal) antibody produced in rabbit

enhanced validation

~1.5 mg/mL, affinity isolated antibody, buffered aqueous solution

Sinônimo(s):

Anti-ATPase type 13A2, Anti-PARK9

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(2)

About This Item

Código UNSPSC:
12352203
NACRES:
NA.41

fonte biológica

rabbit

Nível de qualidade

200

conjugado

unconjugated

forma do anticorpo

affinity isolated antibody

tipo de produto de anticorpo

primary antibodies

clone

polyclonal

Formulário

buffered aqueous solution

peso molecular

antigen ~129 kDa

reatividade de espécies

mouse, human

validação aprimorada

recombinant expression
Learn more about Antibody Enhanced Validation

concentração

~1.5 mg/mL

técnica(s)

western blot: 1-2 μg/mL using mouse brain extract (S1 fraction)
western blot: 2-4 μg/mL using extract of HEK-293T cells expressing human ATP13A2

nº de adesão UniProt

Q9NQ11

Condições de expedição

dry ice

temperatura de armazenamento

−20°C

modificação pós-traducional do alvo

unmodified

Informações sobre genes

human ... ATP13A2(23400)
mouse ... Atp13a2(74772)

Categorias relacionadas

Descrição geral

ATP13A2 is a member of the P5 family of ATPases which function in the transport of inorganic cations.
ATPase type 13 A2 (ATP13A2), also known as Parkinson′s disease 9 (PARK9), codes for P-type ATPase that is present on the lysosomal membrane with ten transmembrane domains.

Aplicação

Anti-ATP13A2 (C-terminal) antibody produced in rabbit has also been used in immunohistochemistry.
Rabbit Anti-ATP13A2 (C-terminal) antibody has be used for immunofluorescence and western blotting assays.

Ações bioquímicas/fisiológicas

ATPase type 13A2 (ATP13A2) plays a vital role in regulation of mitochondrial bioenergetics by macroautophagy. Mutations in the ATP13A2 gene leads to the development of hereditary form of Parkinson associated with dementia, known as Kufor-Rakeb syndrome (KRS).

forma física

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Exoneração de responsabilidade

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Não está encontrando o produto certo?  

Experimente o nosso Ferramenta de seleção de produtos.

Código de classe de armazenamento

10 - Combustible liquids

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Equipamento de proteção individual

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
109M4834V
21190824
106M4799V
108K4753

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Karen E Murphy et al.
Acta neuropathologica communications, 1, 11-11 (2013-11-21)
ATP13A2 (PARK9) loss of function mutations are a genetic cause of an early-onset form of Parkinson's disease (PD), with in vitro studies showing that ATP13A2 deficits lead to lysosomal and mitochondrial dysfunction and α-synuclein accumulation, while elevated ATP13A2 expression reduces
Aaron M Gusdon et al.
Neurobiology of disease, 45(3), 962-972 (2011-12-27)
Mitochondrial dysfunction and autophagy are centrally implicated in Parkinson's disease (PD). Mutations in ATP13A2, which encodes a lysosomal P-type ATPase of unknown function, cause a rare, autosomal recessive parkinsonian syndrome. Lysosomes are essential for autophagy, and autophagic clearance of dysfunctional
David Ramonet et al.
Human molecular genetics, 21(8), 1725-1743 (2011-12-22)
Mutations in the ATP13A2 gene (PARK9, OMIM 610513) cause autosomal recessive, juvenile-onset Kufor-Rakeb syndrome and early-onset parkinsonism. ATP13A2 is an uncharacterized protein belonging to the P(5)-type ATPase subfamily that is predicted to regulate the membrane transport of cations. The physiological
Jason P Covy et al.
Journal of neuroscience research, 90(12), 2306-2316 (2012-08-01)
Mutations in ATP13A2, which encodes a lysosomal P-type ATPase of unknown function, cause an autosomal recessive parkinsonian syndrome. With mammalian cells, we show that ATP13A2 expression protects against manganese and nickel toxicity, in addition to proteasomal, mitochondrial, and oxidative stress.

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica